Join our daily newsletter At The Bell to receive exclusive market insights
- Mesoblast’s (MSB) lead product candidate has come out on top at the Fierce Innovation Awards
- The company’s remestemcel-L treatment, which has recently been tested against acute respiratory distress syndrome (ARDS) in COVID-19 patients, won the prestigious ‘Fierce Biotech Innovation of the Year’ award
- Remestemcel-L is also being trialled as a treatment for children with steroid-refractory acute graft versus host disease (SR-aGVHD)
- This is a potentially life-threatening complication which can develop when a patient undergoes a bone marrow transplant
- Currently, the drug is under priority review with the U.S. Food and Drug Administration (FDA)
- The dual-listed healthcare stock has a pipeline of other clinical treatments and is primarily focussed on cellular medicines
- Following the news, shares in the ASX 200-lister shot up 7.97 per cent to trade for just over $5 each
Mesoblast’s (MSB) lead product candidate has come out on top at the Fierce Innovation Awards.
The peer-reviewed awards program is the brainchild of the FierceBiotech and FiercePharma publisher, a way to celebrate the best and brightest in the biotech space.
The company’s remestemcel-L treatment, which has recently been tested against acute respiratory distress syndrome (ARDS) in COVID-19 patients, won the prestigious ‘Fierce Biotech Innovation of the Year’ award.
Remestemcel-L is also being trialled as a treatment for children with steroid-refractory acute graft versus host disease (SR-aGVHD), a potentially life-threatening complication when a patient undergoes a bone marrow transplant.
Currently, the drug is under priority review with the U.S. Food and Drug Administration (FDA). The major clinical body is evaluating the treatment, and, if approved, remestemcel-L could launch in the states as soon as this year. This treatment is already available in Japan under the ‘RYONCIL’ label.
“This important award is recognition of Mesoblast’s leadership as an innovator in the cell therapy industry, and of the potential for remestemcel-L to profoundly impact the lives of children suffering with SR-aGVHD,” Mesoblast CEO Dr Silviu Itescu commented.
The dual-listed healthcare stock has a pipeline of other clinical treatments and is primarily focussed on cellular medicines.
Following the news, shares in the ASX 200-lister shot up 7.97 per cent to trade for just over $5 each at 11:35 am AEST.
